SC
TNGX icon

SummitTX Capital’s Tango Therapeutics TNGX Stock Holding History

SummitTX Capital’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,535
Closed -$262K – 1019
2026
Q1 		$262K Buy
+12,535
New +$174K 0.01% 664

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

SummitTX Capital's TNGX Position: Q2 2026 in Review

SummitTX Capital sold out of Tango Therapeutics (TNGX) in Q2 2026, closing a stake of 12,535 shares — an estimated $262K sold.

SummitTX Capital first reported a position in TNGX in Q1 2026 and held it in 1 quarter. The position peaked at $262K in Q1 2026. 247 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • SummitTX Capital reported no remaining Tango Therapeutics position as of Q2 2026 after selling out during the quarter.
  • SummitTX Capital sold 12,535 Tango Therapeutics shares in Q2 2026, an estimated $262K.
  • SummitTX Capital first reported a position in Tango Therapeutics in Q1 2026 and held it in 1 quarter.
  • SummitTX Capital's Tango Therapeutics position peaked at $262K in Q1 2026.
  • 247 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.